

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

Filed by the Registrant /X/

Filed by a Party other than the Registrant / /

Check the appropriate box:

/X/ Preliminary Proxy Statement

/ / Definitive Proxy Statement

/ / Definitive Additional Materials

/ / Soliciting Material Pursuant to Section 240.14a-11(c) or Section
240.142-12

ABBOTT LABORATORIES

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement)

Payment of Filing Fee (Check the appropriate box):

/X/ \$125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), or 14a-6(j)(2)

/ / \$500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3)

/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(4)
and 0-11

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:*

4) Proposed maximum aggregate value of transaction:

* Set forth the amount on which the filing fee is calculated and state how it
was determined.

/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.

1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

[PHOTO--a description of this photo
appears on the following page and
also in appendix in the
EDGAR version]

ABBOTT LABORATORIES
Notice of
Annual Meeting
of Shareholders
and
Proxy Statement
1994

[LOGO]

ABBOTT LABORATORIES
ONE ABBOTT PARK ROAD
ABBOTT PARK, ILLINOIS 60064-3500 U.S.A.

COVER:

USING HYTRIN-R- TO TREAT THE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH) HAS ALLOWED FRANK SMOCZYNSKI TO RETURN TO AN ACTIVE LIFESTYLE. FRANK, AN ENTREPRENEUR AND AVID OUTDOORSMAN FROM ST. CHARLES, ILL., IS SHOWN ENJOYING A QUIET MOMENT OF FLY FISHING IN THE MISSOURI OZARKS.

HYTRIN-R- IS ABBOTT'S ONCE-A-DAY ALPHA BLOCKER FOR THE TREATMENT OF HYPERTENSION AND SYMPTOMATIC BPH. BPH IS A CONDITION OF THE PROSTATE GLAND THAT IS COMMON IN MEN OVER 50. IN SOME CASES, HYTRIN-R- REPRESENTS AN ALTERNATIVE TO SURGICAL PROCEDURES. HYTRIN-R- RECEIVED U.S. MARKETING CLEARANCE FOR BPH IN SEPTEMBER, AND CONTINUES TO GAIN MOMENTUM IN INTERNATIONAL MARKETS.

Your Vote
Is Important

Please sign and promptly return your
proxy in the enclosed envelope.

Notice of Annual Meeting
of Shareholders

The Annual Meeting of the Shareholders of Abbott Laboratories will be held at
the corporation's headquarters, One Abbott Park Road, at the intersection of
Route 137 and Waukegan Road, Lake County, Illinois, on Friday, April 29, 1994 at
9:00 a.m. for the following purposes:

- (1) To elect thirteen directors to hold office during the
year following the Annual Meeting or until their successors are elected (Item
No. 1 on Proxy Card);
- (2) To ratify the appointment of Arthur Andersen & Co.
as auditors of the corporation (Item No. 2 on Proxy Card);
- (3) To amend the corporation's Articles of
Incorporation to limit certain liabilities of directors and to amend the
indemnification provisions for directors, officers and employees to the extent
permitted by Illinois law (Item No. 3 on Proxy Card); and
- (4) To transact such other business as may properly
come before the meeting, including consideration of the shareholder proposals on
pharmaceutical pricing and infant formula, if such proposals are presented at
the meeting.

The board of directors recommends that you vote FOR Items 1, 2 and 3 on the
proxy card. The board of directors OPPOSES both shareholder proposals and
recommends that you vote AGAINST Item Nos. 4 and 5 on proxy card.

The close of business March 2, 1994 has been fixed as the record date for
determining the shareholders entitled to receive notice of, and to vote at, the
Annual Meeting.

Admission to the meeting will be by admission card only. If you plan to attend,
please complete and return the reservation form on the inside back cover, and an
admission card will be sent to you.

By order of the board of directors.

LAEL F. JOHNSON
SECRETARY
March 4, 1994

ABBOTT LABORATORIES
PROXY STATEMENT

SOLICITATION OF PROXIES

The accompanying proxy is solicited on behalf of the board of directors for use at the Annual Meeting of Shareholders. The meeting will be held on April 29, 1994 at the corporation's headquarters, One Abbott Park Road, at the intersection of Route 137 and Waukegan Road, Lake County, Illinois. The corporation will bear the cost of making solicitations from its shareholders and may enlist the help of banks and brokerage firms in soliciting proxies from their customers. The corporation will reimburse these institutions for out-of-pocket expenses. Proxies may also be solicited by mail or in person by directors, officers, or employees of the corporation and its subsidiaries. The corporation has also retained Georgeson & Company Inc. to aid in the solicitation of proxies, at an estimated cost of \$10,000 plus reimbursement for reasonable out-of-pocket expenses.

VOTING SECURITIES AND RECORD DATE

Shareholders of record at the close of business on March 2, 1994 will be entitled to notice of, and to vote at, the Annual Meeting. As of January 31, 1994, the corporation had 819,811,254 outstanding common shares, which are the only outstanding voting securities.

VOTING OF PROXIES

A shareholder may vote in person, by a duly executed proxy, or through an authorized representative. The bylaws provide that a shareholder may authorize no more than three persons as proxies to attend and vote at the meeting. Proxies may be revoked at any time prior to the meeting. This may be done by written notice delivered to the secretary of the corporation, or by signing and delivering a proxy with a later date.

All shareholders have cumulative voting rights in the election of directors and one vote per share on all other matters. Cumulative voting allows a shareholder to multiply the number of shares owned by the number of directors to be elected and to cast the total for one nominee or distribute the votes among the nominees as the shareholder desires. Nominees who receive the greatest number of votes will be elected.

Unless authority is withheld in accordance with instructions on the proxy, the persons named in the proxy will vote the shares covered by proxies they receive to elect the 13 nominees hereinafter named. These shares may be voted cumulatively so that one or more of the nominees may receive fewer votes than the other nominees (or no votes at all). Should a nominee become unavailable to serve, the shares will be voted for a substitute designated by the board of directors, or for fewer than 13 nominees if, in the judgment of the proxy holders, such action is necessary or desirable.

Where a shareholder has specified a choice for or against ratification of Arthur Andersen & Co. as auditors, the amendment of the Articles of Incorporation, or either or both of the shareholder proposals, or has abstained on these matters, the shares represented by the proxy will be voted as specified. Where no choice has been specified, the proxy will be voted FOR ratification of Arthur Andersen & Co. as auditors, FOR the amendment of the Articles of Incorporation, and AGAINST both shareholder proposals. A proxy may indicate that all or a portion of the shares represented by such proxy are not being voted with respect to a particular matter. This could occur, for example, when a broker or bank is not permitted to vote stock held in street name on certain matters in the absence of instructions from the beneficial owner of the stock. These "non-voted shares" will be considered shares not present and entitled to vote on such matter, although such shares may be considered present and entitled to vote for other purposes and will count for purposes of determining the presence of a quorum. Non-voted shares will not affect the determination of the outcome of the vote on any matter to be decided at the meeting.

The affirmative vote by the holders of two-thirds of the outstanding common shares entitled to vote at the meeting is required for adoption of the proposal to amend the Articles of Incorporation. With respect to all other matters, a favorable vote of a majority of the shares represented at the meeting and entitled to vote on these matters are required for approval. Abstentions and withheld votes have the effect of votes against all of these matters.

The board of directors is not aware of any other issue to be brought before the meeting. If other matters are properly brought before the meeting, the accompanying proxy will be voted in accordance with the judgment of the proxy holders.

- - - - -

INFORMATION CONCERNING SECURITY OWNERSHIP

On January 31, 1994, the Abbott Laboratories Stock Retirement Trust, c/o Abbott Laboratories, One Abbott Park Road, Abbott Park, Illinois 60064-3500, held 64,548,391 common shares (approximately 7.9 percent of the outstanding common shares) of the corporation. These shares were held for the individual accounts of approximately 35,148 employees and other plan participants who participate in the Abbott Laboratories Stock Retirement Plan. The trustees of the Stock Retirement Trust are G. P. Coughlan, T. C. Freyman, and E. M. Walvoord, officers of the corporation. The trustees share voting power with respect to the shares owned by the Trust. The trustees must solicit and follow voting instructions from the participants if the trustees determine that a matter to be voted on at a shareholder meeting could materially affect the interests of participants. The individual participants have investment power over these shares, as provided by the terms of the Trust. The Trust Agreement is of unlimited duration.

- - - - -

COMMITTEES OF THE BOARD OF DIRECTORS

The board of directors, which held six meetings in 1993, has four committees established in the corporation's bylaws: the executive committee, audit committee, compensation committee, and nominations committee.

The executive committee, whose members are D. L. Burnham, chairman, H. L. Fuller, W. D. Smithburg, J. R. Walter, and W. L. Weiss, held one meeting in 1993. This committee may exercise all the authority of the board in the management of the corporation except for matters expressly reserved by law for board action.

The audit committee, whose members are J. R. Walter, chairman, K. F. Austen, H. L. Fuller, The Lord Hayhoe PC, A. F. Jacobson, and W. L. Weiss, held two meetings in 1993. This committee provides advice and assistance regarding accounting, auditing, and financial reporting practices of the corporation. Each year, it recommends to the board a firm of independent public accountants to serve as auditors. The audit committee reviews with such auditors the scope and results of their audit, fees for services, and independence in servicing the corporation. The committee also meets with the corporation's internal auditors to evaluate the effectiveness of the work they perform.

The compensation committee, whose members are W. D. Smithburg, chairman, H. L. Fuller, A. F. Jacobson, D. A. Jones, B. Powell, Jr., A. B. Rand, W. A. Reynolds, and J. R. Walter, held five meetings in 1993. This committee is responsible for setting and administering the policies and programs that govern both annual compensation and stock ownership programs.

The nominations committee, whose members are W. A. Reynolds, chairman, K. F. Austen, D. A. Jones, B. Powell, Jr., A. B. Rand, W. D. Smithburg, and W. L. Weiss, held two meetings in 1993. This committee develops general criteria regarding the qualifications and selection of board members and officers, and recommends candidates for such positions to the board of directors. A shareholder may recommend persons as potential nominees for director or directly nominate persons for director by complying with the procedures on pages 15 and 16.

The average attendance of all directors at board and committee meetings in 1993 was 97 percent.

INFORMATION CONCERNING NOMINEES FOR DIRECTORS
(ITEM NO. 1 ON PROXY CARD)

Thirteen directors are to be elected to hold office until the next Annual Meeting or until their successors are elected. All of the nominees are currently serving as directors.

EXECUTIVE COMPENSATION

Report of the Compensation Committee

The compensation committee of the board of directors is composed entirely of directors who have never been employees of the corporation. The committee is responsible for setting and administering the policies and programs that govern both annual compensation and stock ownership programs.

The foundation of the executive compensation program is based on principles designed to align compensation with the corporation's business strategy, values and management initiatives. The program:

- Integrates compensation programs with both the corporation's annual and long-term strategic planning and measurement processes.
- Supports a performance-oriented environment that rewards actual performance that is related to both goals and performance of the corporation as compared to that of industry performance levels.
- Helps attract and retain key executives critical to the long-term success of the corporation.

The key components of the compensation program are base salary, annual incentive award, and equity participation. These components are administered with the goal of providing total compensation that is competitive in the marketplace, recognizes meaningful differences in individual performance and offers the opportunity to earn above average rewards when merited by individual and corporate performance.

The marketplace is defined by comparing the corporation to a group of major corporations with similar characteristics including industry and technology emphasis. These companies include the majority of companies in the Standard and Poor's Healthcare Composite Index. A select group of non-healthcare companies chosen for size and performance comparability to the corporation is used as a secondary source of comparison.

Using compensation survey data from the comparison groups, a target for total compensation and each of its elements, base, incentive, and equity-based compensation is established. The intent is to deliver total compensation that will be in the upper range of pay practices of peer companies when merited by the corporation's performance. To achieve this objective, a substantial portion of executive pay is delivered through performance-related variable compensation programs which are based upon achievement of the corporation's goals. Each year the committee reviews the elements of executive compensation to ensure that the total compensation program, and each of its elements, meets the overall objectives discussed above.

In 1993, total compensation was paid to executives based on individual performance and on the extent to which the business plans for their areas of responsibility were achieved or exceeded. On balance, performance goals were substantially met or exceeded and therefore compensation was paid accordingly.

Base compensation was determined by an assessment of each executive's performance, current salary in relation to the salary range designated for the job, experience, and potential for advancement as well as by the performance of the corporation. While many aspects of performance can be measured in financial terms, the committee also evaluated the success of the management team in areas of performance that cannot be measured by traditional accounting tools, including the development and execution of strategic plans, the development of management and employees, and the exercise of leadership within the industry and in the communities that Abbott serves.

The Abbott Management Incentive Plan is designed to reward executives when the corporation achieves certain financial objectives and when each executive's area of responsibility meets its predetermined goals. These goals include financial elements such as profitability, total sales, and earnings per share and non-financial elements such as the achievement of selected strategic goals and the successful development of human resources. Among these goals the committee gives particular weight to the achievement of overall profitability and earnings per share targets as documented in the corporation's business plans.

The corporation has provided forms of equity participation as a key part of its total program for motivating and rewarding executives and managers for many years. Grants of stock options and restricted stock have provided an important part of the equity link to shareholders. Through these vehicles, the corporation has encouraged its executives to obtain and hold the corporation's stock.

Targeted award ranges for stock options and restricted stock opportunities are determined taking into account competitive marketplace practice. Actual individual awards are determined based on the established competitive target and individual performance. The committee considers the amounts of options and

restricted stock previously granted and the aggregate size of current awards in deciding to award additional options and restricted stock.

The committee believes that equity participation helps create a long-term partnership between management/ owners and other shareholders. The policy of granting stock options on a regular basis and encouraging stock ownership has played a strong part in retaining an excellent team of executives and managers.

As reflected in the corporation's financial statements, Abbott's performance in 1993 included 7.1% growth in sales, and 15.0% growth in earnings per share. This performance is in the upper range of performance level among peer companies. In light of this performance and competitive evaluation, the committee determined to grant Mr. Burnham, the corporation's Chairman and Chief Executive Officer, a 2.8% increase in base salary, a 6.2% increase in bonus, a restricted stock award and stock option grants.

Preliminary regulations interpreting The Omnibus Budget Reconciliation Act of 1993 were issued in late December, 1993. The committee intends during 1994 to review the impact of this act on the corporation's executive remuneration once final regulations are issued.

COMPENSATION COMMITTEE

W. D. Smithburg, chairman, H. L. Fuller, A. F. Jacobson, D. A. Jones, B. Powell, Jr., A. B. Rand, W. A. Reynolds, and J. R. Walter.

Summary Compensation Table

The following table summarizes compensation earned in 1993, 1992 and 1991 by the Chief Executive Officer and the four other most highly paid executive officers (the "named officers") in 1993.

Name and Principal Position	Year	Annual Compensation			Long-term Compensation		All Other Compensation (\$)(5)
		Salary (\$)(1)	Bonus (\$)	Other Annual Compensation (\$)	Restricted Stock Award(s) (\$)(2)	Options/SARs (#)	
Duane L. Burnham Chairman of the Board, Chief Executive Officer and Director	1993	\$772,615	\$725,000	\$ 192,449	\$787,500(3)	195,000	\$ 24,306
	1992	761,535	682,500	64,592	823,125(4)	120,000	6,078
	1991	690,422	650,000	100,095	0	100,002	5,951
Thomas R. Hodgson President, Chief Operating Officer and Director	1993	554,146	605,000	62,036	472,500(3)	130,002	17,857
	1992	512,063	550,000	31,303	548,750(4)	70,008	6,226
	1991	454,528	500,000	38,046	0	60,000	6,097
Paul N. Clark Senior Vice President, Pharmaceutical Operations	1993	332,692	362,500	7,552	0	0	8,722
	1992	330,252	340,000	6,369	329,250(4)	84,024	6,048
	1991	302,635	310,000	35	0	30,000	5,922
Gary P. Coughlan Senior Vice President, Finance and Chief Financial Officer	1993	395,385	360,000	27,627	0	0	12,220
	1992	393,525	330,000	13,255	329,250(4)	81,324	5,959
	1991	362,088	300,000	13,642	0	30,000	0
David A. Thompson Senior Vice President, Diagnostic Operations	1993	342,692	385,000	45,629	0	0	11,274
	1992	340,608	385,000	18,436	329,250(4)	84,024	6,345
	1991	312,608	350,000	19,303	0	30,000	6,213

TABLE FOOTNOTES

- (1) The 1993 and 1991 amounts reflect 26 two-week pay periods. The 1992 amounts reflect 27 two-week pay periods.
- (2) The number and value of restricted shares held as of December 31, 1993 were as follows: D. L. Burnham - 78,000/\$2,310,750; T. R. Hodgson - 43,600/\$1,291,650; P. N. Clark - 16,000/\$474,000; G. P. Coughlan - 28,800/\$853,200; and D. A. Thompson - 16,000/\$474,000. The officers receive all dividends paid on these shares.
- (3) The number of shares covered by these awards are 30,000 for Mr. Burnham and 18,000 for Mr. Hodgson. These awards vest in three equal installments on January 10, 1994, 1995 and 1996.
- (4) The number of shares covered by these awards and the number of shares vested, respectively, are as follows: D. L. Burnham - 30,000 and 6,000; T. R. Hodgson - 20,000 and 4,000; P. N. Clark - 12,000 and 2,400; G. P. Coughlan - 12,000 and 2,400; and D. A. Thompson - 12,000 and 2,400. The remaining shares covered by the awards vest five years from the date of grant.
- (5) Employer contributions made to the Stock Retirement Plan and employer

contributions made or accrued with respect to the 401(k) Supplemental Plan.

Stock Options

The following tables summarize the named officers' stock option activity during 1993.

Option/SAR Grants in Last Fiscal Year

Name	Individual Grants		Exercise or Base Price (\$/Sh.)	Expiration Date (2)	Potential Realizeable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term (3):
	Number of Securities Underlying Options/SARs Granted (#)(1)	% of Total Options/SARs Granted to Employees in Fiscal Year			5% (\$)
Duane L. Burnham	150,000	11.0%	\$ 25.32	04/16/03	\$2,388,543
	45,000	3.3	26.26	09/10/03	743,165
Thomas R. Hodgson	90,000	6.6	25.32	04/16/03	1,433,126
	40,002	2.9	26.26	09/10/03	660,624
Paul N. Clark	0	0.0	N/A	N/A	N/A
Gary P. Coughlan	0	0.0	N/A	N/A	N/A
David A. Thompson	0	0.0	N/A	N/A	N/A
Gain for all Shareholders at Assumed Rates for Appreciation (4):					15,298,478,946

Name	10% (\$)
Duane L. Burnham	\$6,053,032 1,883,325
Thomas R. Hodgson	3,631,819 1,674,150
Paul N. Clark	N/A
Gary P. Coughlan	N/A
David A. Thompson	N/A
Gain for all Shareholders at A	38,769,315,121

TABLE FOOTNOTES

- (1) Limited stock appreciation rights have been granted in tandem with these options.
- (2) One-third of the shares covered by these options are exercisable after one year; two-thirds after two years; and all after three years.
- (3) The dollar amounts under these columns are the result of calculations at the 5% and 10% rates required by the SEC and, therefore, are not intended to forecast possible future appreciation, if any, of the stock price.
- (4) Amounts were determined using total shares outstanding at December 31, 1993 of 821,129,684 and December 31, 1993 closing market price of \$29.625 per share.

Aggregated Option/SAR Exercises in Last Fiscal Year and FY-end Option/SAR Values

Name	Shares Acquired on Exercise (#)	Value Realized (\$)	Number of Securities Underlying Unexercised Options/SARs at Fiscal Year-end (#) Exercisable/Unexercisable	Value of Unexercised In-the-Money Options/SARs at Fiscal Year-end (\$) Exercisable/Unexercisable

Duane L. Burnham	0	\$ 0	153,336/328,334	\$1,221,858/986,824
Thomas R. Hodgson	8,860	160,853	61,670/208,342	293,047/638,282
Paul N. Clark	0	0	138,724/80,020	1,850,176/45,925
Gary P. Coughlan	0	0	83,556/77,770	714,297/45,925
David A. Thompson	0	0	215,372/80,020	3,287,516/45,925

Annuity Retirement Plan

The corporation and certain subsidiaries maintain a defined benefit pension plan known as the Abbott Laboratories Annuity Retirement Plan covering most employees in the United States, age 21 or older. Pension benefits are generally based on service and eligible earnings for the 60 consecutive months within the final 120 months of employment for which eligible earnings were highest. Pension benefits are offset for Social Security benefits.

The following table shows the estimated annual benefits payable to employees upon normal retirement. The amounts shown are computed on a straight life annuity basis and include Social Security off-sets and supplemental benefits under a nonqualified supplemental pension plan. The supplemental pension plan provides benefits not available under the Annuity Retirement Plan. The compensation considered in determining the pensions payable to the named officers is the compensation shown in the "Salary" and "Bonus" columns of the Summary Compensation Table on page 8.

Pension Plan Table

Remuneration	Years of Service				
	15	20	25	30	35
\$ 700,000	\$ 234,546	\$ 312,728	\$ 364,660	\$ 385,092	\$ 384,524
900,000	302,046	402,728	469,660	496,092	495,524
1,100,000	369,546	492,728	574,660	607,092	606,524
1,300,000	437,046	582,728	679,660	718,092	717,524
1,500,000	504,546	672,728	784,660	829,092	828,524
1,700,000	572,046	762,728	889,660	940,092	939,524
1,900,000	639,546	852,728	994,660	1,051,092	1,050,524

The table above covers the aggregate pension accrued under both the Annuity Retirement Plan and the supplemental pension plan. Pensions accrued under the Annuity Retirement Plan are funded through a trust known as the Abbott Laboratories Annuity Retirement Trust, established on behalf of all participants in that plan. Pensions accrued under the nonqualified supplemental pension plan with present values exceeding \$100,000 are funded through individual trusts established on behalf of the participants in that plan. During 1993, the following amounts, less applicable tax withholdings, were deposited in such individual trusts established on behalf of the named officers: D. L. Burnham, \$1,279,254; T. R. Hodgson, \$1,119,675; P. N. Clark, \$51,271; and D. A. Thompson, \$446,871. As of December 31, 1993, the years of service credited under the Plan for the named officers were as follows: D. L. Burnham - 11; T. R. Hodgson - 21; P. N. Clark - 9; G. P. Coughlan - 3; and D. A. Thompson - 22.

Compensation of Directors

Employees of the corporation are not compensated for serving on the board or on board committees. Non-employee directors are compensated under the Abbott Laboratories Non-Employee Directors' Fee Plan in the amounts of \$4,167 for each month of service as director and \$667 for each month of service as chairman of a board committee (\$1,600 for each month of service as chairman of the executive committee).

Fees earned under this Plan are paid in cash to the director, or deferred (as a non-funded obligation of the corporation or paid into a secular trust established by the director) until payments commence (generally at age 65 or upon retirement from the board of directors). If the fees are deferred, the director may elect to have the fees credited to a stock equivalent account under which the fees accrue the same return they would have earned if invested in common shares of the corporation. Interest is accrued annually on deferred fees not credited to a stock equivalent account.

Under the Plan, the corporation may grant a director who retires from the board a retirement benefit, and such benefit will be payable to the surviving spouse of any director who dies while serving as a director. The retirement benefit consists of payment of an amount equal to the monthly director's fee in effect on the date the director retires (or, for a director who dies, the fee in effect on the date of death) for a period equal to his or her service on the board to a maximum of 120 months. In return for the retirement benefit, the director agrees to provide consulting services to the board.

In 1993, each non-employee director was granted a restricted stock award of 790 shares. The shares are nontransferable prior to termination, retirement from the board, death, or a change in control of the corporation. The non-employee directors are entitled to vote the shares and receive all dividends paid on the shares.

K. F. Austen, a non-employee director, performed services during 1993 for the corporation under a consulting agreement. The consulting agreement provides that the fees he earns under the agreement may receive the same treatment as fees earned under the Abbott Laboratories Non-Employee Directors' Fee Plan. Dr. Austen served as Chairman of the corporation's Scientific Advisory Council until March 31, 1993 and provided consultation in the areas of research and development, new technology and immunopharmacology throughout 1993. In 1993, Dr. Austen received \$50,000 for his consulting services.

Compensation Committee Interlocks and Insider Participation

The persons who served as members of the compensation committee of the corporation's board of directors during 1993 are named on page 2, "Committees of the Board of Directors."

Performance Graph

The following graph compares the change in the corporation's cumulative total shareholder return on its common shares with the Standard and Poor's 500 Stock Index and the Standard and Poor's Healthcare Composite Index.

[GRAPHIC]
filed under cover of Form SE on February 15, 1994

Security Ownership of Officers and Directors

The table below reflects the numbers of common shares beneficially owned by the directors, the named officers, and all directors and executive officers of the corporation as a group as of January 31, 1994. It also reflects the number of equivalent stock units held by non-employee directors under the Abbott Laboratories Non-Employee Directors' Fee Plan described on page 10 and by K. F. Austen under the consulting agreement described on page 10.

NAME	SHARES BENEFICIALLY OWNED, EXCLUDING OPTIONS (1)(2)	EQUIVALENT STOCK UNITS
K. Frank Austen, M.D.	9,128	1,914
Duane L. Burnham	438,029	0
Paul N. Clark	102,205	0
Gary P. Coughlan	74,916(3)	0
H. Laurance Fuller	13,196	11,594
The Lord Hayhoe PC	5,396	0
Thomas R. Hodgson	393,906	0
Allen F. Jacobson	2,790	1,132
David A. Jones	118,192	35,529

NAME	SHARES BENEFICIALLY OWNED, EXCLUDING OPTIONS (1)(2)	EQUIVALENT STOCK UNITS
Boone Powell, Jr.	9,528	20,069
Addison Barry Rand	3,130	0
W. Ann Reynolds, Ph.D.	11,765	20,413
William D. Smithburg	16,786	33,324
David A. Thompson	110,988(3)	0
John R. Walter	5,628	7,100
William L. Weiss	20,728	4,339
All directors and executive officers as a group (32 persons) (3)(4)	2,436,639	135,414

TABLE FOOTNOTES

- (1) The number of unexercised option shares which were exercisable within 60 days after January 31, 1994 were: D. L. Burnham, 153,336; T. R. Hodgson, 61,670; P. N. Clark, 138,724; G. P. Coughlan, 83,556; D. A. Thompson, 215,372; and all executive officers as a group (21 persons), 1,852,522.
- (2) The table includes the shares held in the named officers' accounts in the Abbott Laboratories Stock Retirement Trust. Each officer has shared voting power and sole investment power with respect to the shares held in his account. As of January 31, 1994 the number of shares held in each named officer's account were: D. L. Burnham, 4,550; T. R. Hodgson, 24,750; P. N. Clark, 2,657; G. P. Coughlan, 2,755; and D. A. Thompson, 32,644.

- (3) G. P. Coughlan is a trustee of the Abbott Laboratories Stock Retirement Trust and has shared voting power with respect to all of the common shares owned by that trust. He is also a director of the Abbott Laboratories Fund and has shared voting and investment power with respect to all of the common shares owned by the fund. D. A. Thompson is a director of the Clara Abbott Foundation and has shared voting and investment power with respect to all of the common shares owned by the foundation. The table does not include these shares. As of January 31, 1994 the Abbott Laboratories Stock Retirement Trust owned 64,548,391 shares (7.9%) of the outstanding shares of the corporation; the Abbott Laboratories Fund owned 1,085,640 shares (.1%) of the outstanding shares of the corporation; and the Clara Abbott Foundation owned 2,851,986 shares (.3%) of the outstanding shares of the corporation.
- (4) Excluding the shares held by G. P. Coughlan in his capacity as a trustee of the Abbott Laboratories Stock Retirement Trust and the shares held by the Abbott Laboratories Fund and the Clara Abbott Foundation, the directors and executive officers as a group together own less than one percent of the outstanding shares of the corporation. (see footnote 3)
-

COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934

The corporation believes that during 1993 its officers and directors complied with all filing requirements under Section 16(a) of the Securities Exchange Act of 1934 except as described below. Thomas R. Hodgson, an officer of the corporation, filed late Initial Statements of Beneficial Ownership of Securities for two trusts of which he is the trustee (reporting the trusts' ownership of 1,440 shares and 960 shares, respectively). A third party gave these shares to these two trusts. The gift of these 960 shares to one of these two trusts was also reported late by Mr. Hodgson on his Annual Statement of Beneficial Ownership of Securities. Gary R. Byers, an officer of the corporation, corrected an error made on his Initial Statement of Beneficial Ownership of Securities form by increasing by 68 shares the number of shares shown as owned on that Initial Statement of Beneficial Ownership of Securities form.

SELECTION OF INDEPENDENT PUBLIC ACCOUNTANTS (ITEM NO. 2 ON PROXY CARD)

The bylaws of the corporation provide that, upon the recommendation of the audit committee, the board of directors shall appoint annually a firm of independent public accountants to serve as auditors, and that such appointment shall be submitted for ratification by the shareholders at the Annual Meeting. The board has appointed Arthur Andersen & Co. to act as auditors for the current year. This firm has served as auditors of the corporation since 1963. The board of directors recommends a vote FOR ratification of the selection of Arthur Andersen & Co. as independent public accountants for 1994.

Representatives of Arthur Andersen & Co. are expected to be present at the Annual Meeting and will be given the opportunity to make a statement if they desire to do so. They will also be available to respond to appropriate questions.

AMENDMENT OF ARTICLES OF INCORPORATION CONCERNING LIABILITY AND INDEMNIFICATION (ITEM NO. 3 ON PROXY CARD)

In 1993 the Illinois legislature adopted an amendment to the Illinois Business Corporation Act (the "Illinois Act") that is similar to amendments adopted to the Delaware General Corporation Law in 1986. This amendment to the Illinois Act allows the limitation of personal liability of directors to the corporation and its shareholders for monetary damages in certain circumstances, and makes changes in the procedure for directors, officers and employees of the corporation to obtain indemnification from the corporation.

The board of directors recommends that the corporation's Articles of Incorporation be amended to (a) limit the personal liability of directors to the corporation and its shareholders for monetary damages, as permitted by the amendment to the Illinois Act, and (b) change the procedure with respect to advancement and repayment of litigation expenses of persons covered under the indemnification provisions of the Articles of Incorporation. Article R-VI of the Articles of Incorporation, as it is proposed to be amended, is set forth in full in Exhibit A attached hereto.

LIMITATION OF LIABILITY

Consistent with the 1993 amendment to the Illinois Act, the proposed amendment to Article R-VI provides that directors will not be personally liable to the corporation or its shareholders for monetary damages except in the case of: (a) breach of the director's duty of loyalty to the corporation or its shareholders, (b) acts or omissions not in good faith or involving intentional misconduct or knowing violation of the law, (c) illegal payment of dividends and certain illegal acts in connection with a dissolution of the corporation, or (d) any transaction in which the director derived an improper personal benefit. The effect of the proposed amendment to Article R-VI is to absolve directors from monetary liability to the corporation or its shareholders for breach of the duty of care, even if the breach involved gross negligence.

The proposed amendment to Article R-VI does not limit the liability of directors for acts or omissions occurring before its adoption. The amendment applies only to the monetary liability of directors arising from a breach of their fiduciary duty to the corporation or its shareholders in connection with their acts or omissions as a director and not to liability arising in other capacities such as an officer. The amendment does not limit the director's liability to parties other than the corporation or its shareholders or liabilities under any other law, including the federal securities laws, or the ability of the corporation and its shareholders to seek equitable relief for a breach of fiduciary duty.

Adoption of the proposed amendment will make the corporation's standard for director's liability consistent with the prevailing standard for director liability and the standard applicable to most other publicly-held corporations. The board of directors also believes that the limitation of personal liability as provided in the amendment will enhance the director's decision-making process by encouraging entrepreneurial decisions which may be in the best interests of the corporation.

CHANGES IN INDEMNIFICATION PROCEDURE

The proposed amendment to Article R-VI also makes certain changes in the procedure for obtaining indemnification from the corporation.

Consistent with the 1993 amendment to the Illinois Act, the amendment provides for advancement of litigation expenses without prior approval of the board of directors, but upon receipt of an undertaking by the person receiving the advance to repay the amount of the advance if it shall ultimately be determined that he or she is not entitled to indemnification.

Under prior law, a corporation could advance litigation expenses to the person entitled to indemnification prior to ultimate disposition of the case, provided the board of directors approved each such advance and the person entitled to indemnification submitted an undertaking agreeing to repay the advance unless that person proved that he or she was entitled to indemnification. The amendment to the Illinois Act dispensed with the requirement of prior approval of each advance and shifted the burden to the corporation to prove that the person receiving the advance was not entitled to indemnification.

Since the corporation's present directors and officers will benefit from the added protection of the amendment, they have a personal interest in its adoption. The changes made to the procedure with respect to advancement and repayment of litigation expenses will apply to proceedings commenced before or after adoption of the amendment, including a pending shareholder derivative action relating to alleged improper marketing practices with respect to the corporation's infant formula products in which all present directors (other than Allen F. Jacobson) and Lael F. Johnson, an officer, of the corporation have been made defendants. As of January 31, 1994 the corporation has advanced litigation expenses aggregating \$12,414 on behalf of such directors and officer in connection with such action.

VOTE REQUIRED

An affirmative vote by the holders of two-thirds of the outstanding common shares entitled to vote at the meeting is required for adoption of this proposal to amend the Articles of Incorporation.

The board of directors recommends that you vote FOR this proposal.

- - - - -

SHAREHOLDER PROPOSALS

Two shareholder proposals have been received. The corporation is advised that the proposals will be presented for action at the Annual Meeting. The proposed resolutions and statement made in support thereof are presented below. The names and addresses of the shareholders submitting these proposals will be furnished by the corporation to any person requesting such information. The board of directors recommends that you vote AGAINST both proposals.

- - - - -

SHAREHOLDER PROPOSAL ON PHARMACEUTICAL PRICING (ITEM NO. 4 ON PROXY CARD)

WHEREAS:

We believe all U.S. citizens and corporate entities are being called to sacrifice and to do their part in bringing about a more just and equitable health care system.

During the 1980s, prescription drug prices increased at almost three times the rate of general inflation in the United States.

The burden of these cost increases has been borne by individual consumers such as the elderly and the underinsured in the retail market as well as increased costs for the institutional health care facilities.

The drug companies have been criticized by citizens, organizations, and U.S. government agencies as being unjust in the reaping of "excessive profits at the expense of millions of U.S. citizens".

The price of drugs is consistently higher in the U.S. retail market than in other industrialized countries.

The drug companies have argued that the higher prices in the U. S. are necessary to recoup research and development costs. While all persons who receive these drugs benefit from the research and development, U.S. consumers bear the burden of these costs.

Pharmaceutical companies' recent efforts to limit overall price increases to inflation have failed to significantly benefit retail consumers due to discounted prices offered to volume purchasers such as HMOs and large purchasing groups.

We believe U.S. citizens want reasonable limits on pharmaceutical prices.

RESOLVED: The shareholders request the Board to create and implement a policy of price restraint of pharmaceutical products for both the average individual

consumer and the institutional purchasers utilizing a combination of approaches to keep drug prices to a reasonable level.

The Board will report to shareholders on positive changes in policies and pricing procedures for our pharmaceutical products by September, 1994.

PROPONENTS' STATEMENT IN SUPPORT OF SHAREHOLDER PROPOSAL ON PHARMACEUTICAL PRICING

In creating this policy the Board should consider a formula whereby the individual price on each of the top five prescription drugs for the retail market based on dollar volume in the U.S. for our company be no higher than 10% of the average price for each of the five drugs in the top five markets of these same drugs in the industrialized world. If the price differential is more than 10% for any one of the drugs, that a voluntary cap be immediately placed on the price of said drug in the U.S. until the differential is within the 10%.

Drug pricing has been a controversial topic for the last few years. Now that we are facing major reforms in our health care system in the U.S. it seems most appropriate that all pharmaceutical companies take their share of the responsibility in this reform effort.

BOARD OF DIRECTORS STATEMENT IN OPPOSITION TO SHAREHOLDER PROPOSAL ON PHARMACEUTICAL PRICING (ITEM NO. 4 ON PROXY CARD)

Your Board of Directors opposes the shareholders' proposal and recommends that you vote AGAINST it.

As a global health care company operating in over one hundred geographic markets with a diverse mix of businesses, Abbott supports the goal of improving the access of people worldwide to a high quality of health care while reducing the rate of growth of health care costs.

Abbott has established itself as a leader in the global health care industry by consistently introducing innovative products that improve the quality of health care for patients, offer user efficiencies and reduce the cost of patient therapy.

The Company has priced its products responsibly and adjusted prices in response to changing market conditions. In 1993, the Company's net prices for its products (including pharmaceuticals) increased .9 percent.

We do not believe that it is in the best interests of Abbott shareholders to adopt rigid pricing structures for any specific geographic location, any specific category of products, or any class of customer.

Pricing decisions for all products developed, manufactured and sold by Abbott must be flexible in order to respond to market dynamics in product and geographic market segments, and to assure the Company's continued ability to invest in research and development across our product lines. It is from this investment that innovation will be reaped to allow the best chance for the United States and other countries to accomplish the difficult goals of expanding access, increasing quality and reducing the rate of growth of health care costs.

Your Board of Directors recommends that you vote AGAINST the proposal.

SHAREHOLDER PROPOSAL ON INFANT FORMULA (ITEM NO. 5 ON PROXY CARD)

WHEREAS - the misuse of infant formula is a serious health problem. When formula is mixed with impure water or inadequate amounts of formula are used in preparation, infants often become sick and many die. In fact UNICEF's Director, James Grant has estimated that over one million babies lives could be saved annually if their mothers breastfed instead of bottlefed. Thus, it is vitally important that infant formula companies do not engage in marketing or promotion practices which undermine breast-feeding and promote formula instead. We are pleased that our company has stated publicly that it endorses breast-feeding as the superior form of infant nutrition and is committed to the principle that its marketing practices do not discourage breast-feeding.

Hiroshi Nakajima, M. D., Ph.D., Director-General of the World Health Organization (WHO) and James P. Grant, Executive Director of UNICEF urge that infant formula companies, "within the context of legal instruments and requirements within countries, comply with the principles of the International Code (of Marketing for Breast-Milk Substitutes) in all countries to the fullest extent possible."

Dr. Nakajima and Mr. Grant further state that "adherence to the International Code of Marketing of Breast-Milk Substitutes in its entirety in all countries is a minimum requirement and only one of several important actions required in order to protect healthy practices in respect of infant and young child feeding."

However, Abbott Ross has still not ended its practice of providing free supplies of formula to hospitals as a marketing tool to encourage that hospital to buy Ross formula unless forbidden to do so by government regulation. This is a clear Code violation. In addition, Abbott continues to face other complaints that it internationally violates the Code.

Our company also faces domestic controversy re. infant formula price fixing and

paid \$140 million in settlement of a court case, and faces other cases that could be very costly.

THEREFORE be it resolved that the shareholders request the Board of Directors to endorse and

implement, within any country's legal context, the International Code of Marketing for Breast-Milk Substitutes wherever it sells infant formula.

PROPOSERS' STATEMENT IN SUPPORT OF SHAREHOLDER PROPOSAL ON INFANT FORMULA

Adopted by the World Health Assembly in 1981 to protect infant health from inappropriate commercial pressures, the WHO/UNICEF Code is a reasonable standard and minimum requirement for infant formula industry behavior.

Addressing the "universality of the Code," Dr. Hiroshi Nakajima, M.D., Director-General of the World Health Organization (WHO), says there is no label such as developed or developing when it comes to promoting breast-feeding. He says the Code has "universal relevance."

"Breast is best" means the preferred feeding for infants in all countries. There should be no national boundaries for the best nutrition and healthiest babies. We want Abbott to commit to following the Code wherever it does business.

We ask you to support this resolution requesting that company policy be consistent with internationally agreed upon health care practices and the aim of the Code "to promote and protect breast-feeding."

BOARD OF DIRECTORS STATEMENT IN OPPOSITION TO SHAREHOLDER PROPOSAL ON INFANT FORMULA
(ITEM NO. 5 ON PROXY CARD)

Your Board of Directors opposes the shareholder proposal, and recommends that you vote AGAINST the proposal.

The WHO Code of Marketing of Breastmilk Substitutes was adopted in May, 1981 by the World Health Assembly as a "resolution and not as a regulation." Governments are urged to give effect to the Code according to the "social and legislative framework" of member nations. (Article 11.1) The application of the Code varies widely from country to country. The United States government voted against the Code in 1981.

Abbott supports the Aims and Principles of the WHO Code,

". . . to contribute to the provision and adequate nutrition for infants, by the protection and promotion of breast-feeding, and by ensuring the proper use of breast-milk substitutes, when these are necessary, on the basis of adequate information and through appropriate marketing and distribution."
(Article 1)

In 1983, Abbott agreed to follow the WHO Code in its entirety in DEVELOPING COUNTRIES.

A series of WHO resolutions subsequent to 1981 clarified the intent of the World Health Assembly that free and low cost formulas for institutions (Article 6.6) should be provided through "normal procurement channels." Abbott has instructed its international field management to eliminate free and low cost supplies to institutions whenever government legislation has been passed, whenever a hospital or group of hospitals request elimination of free supplies, or whenever common business practice in a local area follows that pattern.

We believe that the promotion of our infant formula products to hospitals is appropriate. Hospitals are obliged to instruct mothers of newborns in proper feeding techniques at discharge whether the infant is breastfed or bottlefed, including a branded name when appropriate.

Furthermore, breastfeeding in the United States has been INCREASING significantly for the past three years in all demographic groups, and hospitals specifically.

Your Board of Directors recommends that you vote AGAINST the proposal.

DATE FOR RECEIPT OF 1995 SHAREHOLDER PROPOSALS

Shareholder proposals for presentation at the 1995 Annual Meeting must be received by the corporation no later than November 16, 1994 to be considered for inclusion in the proxy statement and proxy for the 1995 meeting.

PROCEDURE FOR RECOMMENDATION AND NOMINATION OF DIRECTORS AND TRANSACTION OF BUSINESS AT ANNUAL MEETINGS

A shareholder may recommend persons as potential nominees for director by submitting the names of such persons in writing to the chairman of the nominations committee or the secretary of the corporation. Recommendations should be accompanied by a statement of qualifications and confirmation of the person's willingness to serve.

A shareholder may directly nominate persons for director only by complying with the following procedure: the shareholder must submit the names of such persons in writing to the secretary of the corporation not earlier

- - - - -

than the October 1 nor later than the February 15 prior to the date of the Annual Meeting. The nominations must be accompanied by a statement setting forth the name, age, business address, residence address, principal occupation, qualifications, and number of shares of the corporation owned by the nominee and the name, record address, and number of shares of the corporation owned by the shareholder making the nomination.

A shareholder may properly bring business before the Annual Meeting of Shareholders only by complying with the following procedure: the shareholder must submit to the secretary of the corporation, not earlier than the October 1 nor later than the February 15 prior to the date of the Annual Meeting, a written statement describing the business to be discussed, the reasons for conducting such business at the Annual Meeting, the name, record address, and number of shares of the corporation owned by the shareholder making the submission, and a description of any material interest of the shareholder in such business.

- - - - -

GENERAL

It is important that proxies be returned promptly. Shareholders are urged, regardless of the number of shares owned, to sign and return their proxy card in the enclosed business reply envelope.

The Annual Meeting will be held at the corporation's headquarters, One Abbott Park Road, located at the intersection of Route 137 and Waukegan Road, Lake County, Illinois. Admission to the meeting will be by admission card only. If you plan to attend the meeting, please complete and return the reservation form. An admission card will be sent to you.

By order of the board of directors.

LAEL F. JOHNSON
SECRETARY

- - - - -

EXHIBIT A

- - - - -

ARTICLE R-VI

1. A director of the corporation shall not be personally liable to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the corporation or its shareholders, (ii) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii) under Section 8.65 of the Illinois Business Corporation Act, or (iv) for any transaction from which the director derived an improper personal benefit; provided that the foregoing provision shall not eliminate or limit the liability of a director for any act or omission occurring before the date this provision became effective.

2. Any person who was or is a party, or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director, officer, employee or agent of the corporation, or who is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall, in the case of persons who are or were directors or officers of the corporation, and may, as to such other persons, be indemnified (and the corporation shall, in the case of persons who are or were directors or officers of the corporation, and may, as to such other persons, advance expenses incurred in defending such actions, suits or proceedings) to the fullest extent now or hereafter permitted by law.

3. The foregoing right of indemnification and advancement of expenses shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise.

- - - - -

[LOGO]

ABBOTT LABORATORIES
ONE ABBOTT PARK ROAD
ABBOTT PARK, ILLINOIS 60064-3500 U.S.A.

NOTICE OF ANNUAL MEETING
OF SHAREHOLDERS
AND PROXY STATEMENT

MEETING DATE
APRIL 29, 1994

YOUR VOTE IS IMPORTANT!

Please sign and promptly return your proxy in the enclosed envelope.

RESERVATION FORM FOR ANNUAL MEETING

I am a shareholder of Abbott Laboratories and plan to attend the Annual Meeting to be held at the corporation's headquarters, One Abbott Park Road, located at the intersection of Route 137 and Waukegan Road, Lake County, Illinois at 9:00 a.m. on Friday, April 29, 1994.

Please send me an admission card.

Name _____
Please Print

Address _____

City _____ State ____ Zip Code _____

Area code and phone number _____

Please complete and return this form in the business reply envelope provided, if you plan to attend the meeting. If you hold your Abbott shares through a broker, it is suggested that you return this form directly to the corporation (rather than through your broker) to ensure timely receipt of an admission card.

SRT

Appendix to Abbott Laboratories 1994 Proxy Statement

On the cover page of the printed document will be a photograph of Frank Smoczynski enjoying a quiet moment of fly fishing in the Missouri Ozarks.

On pages 3 through 6 of the printed document, a photograph of each of the members of the Abbott Laboratories Board of Directors will appear alongside his or her name.

PROXY

ABBOTT LABORATORIES
SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned, revoking previous proxies, acknowledges receipt of the Notice and Proxy Statement dated March 4, 1994 in connection with the Annual Meeting of Shareholders of Abbott Laboratories to be held at 9:00 a.m. on April 29, 1994 at the corporation's headquarters, and hereby appoints DUANE L. BURNHAM and LAEL F. JOHNSON, or either of them, proxy for the undersigned, with power of substitution, to represent and vote all shares of the undersigned upon all matters properly coming before the Annual Meeting or any adjournments thereof.

INSTRUCTIONS: If you wish to vote in accordance with the Board of Directors' recommendations, just sign on the reverse side. You need not mark any boxes.

SEE REVERSE
SIDE

(Important - Please sign and date on other side.)

/x/ Please mark
votes as in
this sample.

// The Board of Directors recommends that you vote FOR items 1,2 and 3.

1. Election of 13 Directors.

Nominees: K.F. Austen, D.L. Burnham, H.L. Fuller, B.J. Hayhoe, T.R. Hodgson,
A.F. Jacobson, D.A. Jones, B. Powell, Jr., A.B. Rand, W.A. Reynolds, W.D.
Smithburg, J.R. Walter, and W.L. Weiss.

For Withhold
// //

MARK HERE
TO REQUEST //
AN ADMISSION
CARD

MARK HERE
FOR ADDRESS //
CHANGE AND
NOTE BELOW

FOR, except to withhold from the following nominee:

2. Ratification of Arthur Andersen & Co. as auditors.

For Against Abstain
// // //

3. Amendment of the Articles of Incorporation.

For Against Abstain
// // //

// The Board of Directors recommends
that you vote AGAINST items 4 and 5.

4. Shareholder Proposal 1 - Pharmaceutical Pricing.

For Against Abstain
// // //

5. Shareholder Proposal 2 - Infant Formula.

For Against Abstain
// // //

Each joint tenant should sign; executors, administrators, trustees, etc. should
give full title and, where more than one is named, a majority should sign.
Please read other side before signing.

Signature(s): _____ Date _____

Signature(s): _____ Date _____